PMID- 15165002
OWN - NLM
STAT- MEDLINE
DCOM- 20041201
LR  - 20181113
IS  - 0391-4097 (Print)
IS  - 0391-4097 (Linking)
VI  - 27
IP  - 3
DP  - 2004 Mar
TI  - Effects of Graves' ophthalmopathy on quality of life.
PG  - 259-64
AB  - General health-related quality of life is markedly impaired in patients with 
      Graves' ophthalmopathy (GO), and even worse than in patients with other chronic 
      conditions like diabetes, emphysema or heart failure. A disease-specific 
      quality-of-life questionnaire for GO has been developed, the so-called GO-QOL, 
      consisting of two subscales: one for visual functioning (8 questions referring to 
      limitations due to decreased visual acuity and/or diplopia) and one for 
      appearance (8 questions referring to limitations in psychosocial functioning due 
      to changes in appearance). The GO-QOL was found to be a valid and reliable 
      instrument. A minimal clinically important difference (MCID) in the GO-QOL score 
      was derived from data obtained before and after specific eye treatments. Based on 
      the patient's opinions, changes of > or = 6 points (minor surgery) or > or = 10 
      points (surgical decompression, immunosuppression) are recommended as MCID. It is 
      concluded that the GO-QOL is an useful instrument for measuring changes over time 
      in visual functioning and appearance of GO patients. The GO-QOL is available in 
      six languages, and can be used as a separate outcome measure in clinical studies.
FAU - Wiersinga, W M
AU  - Wiersinga WM
AD  - Department of Endocrinology and Metabolism, Academic Medical Center, University 
      of Amsterdam, The Netherlands. w.m.wiersinga@amc.uva.nl
FAU - Prummel, M F
AU  - Prummel MF
FAU - Terwee, C B
AU  - Terwee CB
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
SB  - IM
MH  - Graves Disease/*psychology/therapy
MH  - Humans
MH  - *Quality of Life
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
RF  - 25
EDAT- 2004/05/29 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/05/29 05:00
PHST- 2004/05/29 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/05/29 05:00 [entrez]
AID - 5389 [pii]
AID - 10.1007/BF03345275 [doi]
PST - ppublish
SO  - J Endocrinol Invest. 2004 Mar;27(3):259-64. doi: 10.1007/BF03345275.